Wednesday, May 21, 2025
CN
  • About
  • Advertise
  • Careers
  • Contact
Money Compass
  • Home
  • Financial News
  • Investment News
  • Other News
    • Bursa News
    • Government News
    • Listing Companies News
    • Oversea Financial & Investment News
  • Interviews
    • Features Interviews
    • Corporate Interviews
  • Financial & Investment Articles
  • PR Newswire
  • Login
No Result
View All Result
Money Compass
Home PR Newswire

Linerase Officially Launches in Malaysia

Money Compass by Money Compass
May 21, 2025
in PR Newswire
0
Linerase Officially Launches in Malaysia
0
SHARES
2
VIEWS
Share on FacebookShare on Twitter

Redefining Natural Skin Regeneration with Collagen Biostimulation

KUALA LUMPUR, Malaysia, May 21, 2025 /PRNewswire/ — Linerase, the advanced collagen biostimulator trusted by aesthetic doctors worldwide, has officially launched in Malaysia. Designed to stimulate the body’s natural collagen production, Linerase, a product distributed by Venusys Medical, offers a revolutionary approach to skin rejuvenation, restoring elasticity, firmness, and youthful radiance through scientifically backed biostimulation.

Related posts

Peter Singer Named to the Inaugural 2025 TIME100 Philanthropy List

Peter Singer Named to the Inaugural 2025 TIME100 Philanthropy List

May 21, 2025
Peter Singer Named to the Inaugural 2025 TIME100 Philanthropy List

Peter Singer Named to the Inaugural 2025 TIME100 Philanthropy List

May 21, 2025


[From left to right] Dr. Lim Ting Song, aesthetic physician and Medical Director at Clique Clinic; Dr. Katerina Gkouvi, Dermatologist from Greece; Professor Andrea Corbo, Founder of Linerase and Dermatologist from Italy; Mr Carlo Berardini, General Manager of Linerase

During the launch event, international expert Professor Andrea Corbo, Founder of Linerase and Dermatologist from Italy and Dr. Katerina Gkouvi, Dermatologist from Greece shared valuable insights into the science behind Linerase and its unique applications. The programme concluded with Dr. Lim Ting Song, aesthetic physician and Medical Director at Clique Clinic presenting results from local clinical trials, highlighting significant improvements in skin quality, elasticity, and resilience following treatment with Linerase.

Science Behind Linerase

Unlike traditional treatments that add volume or temporarily mask aging, Linerase directly targets the fibroblasts of our skin, which are essentially the cells that act as collagen factories within the skin. Upon being exposed to Linerase, these fibroblasts are stimulated to multiply themselves. Furthermore, Linerase also provides amino acids to these newly-formed fibroblasts, which are utilized as raw materials in the formation of new collagen. All of these effects work in tandem to significantly enhance the production of Type III collagen within our skin. This process helps restore skin firmness, improve texture, and support long-term skin regeneration. Its key indications include:

  • Restoring skin elasticity and firmness in the face, neck, décolletage, and other body areas
  • Improving atrophic skin conditions such as stretch marks, acne scars, post-surgical scars, and trauma lesions

Formulated with Heterologous Type I Collagen (HTIC) derived from equine sources, Linerase breaks down into amino acids and tripeptides upon hydrolysis. The tripeptides stimulate the formation of new fibroblasts and inhibit collagen-degrading enzymes, while the amino acids support the production of Type III collagen. This results in exceptional biocompatibility, promotes effective wound healing, and supports dermo-epidermal regeneration — all while maintaining a strong safety profile with no reported immune responses to date.

Linerase stands out in the field of regenerative aesthetics by stimulating the production of Type III collagen — a critical component in tissue repair, skin elasticity, and neovascularization. Its uniquely low molecular weight formulation (under 1 kiloDalton) significantly reduces the risk of allergenic reactions and granuloma formation, remaining well below the 10 kiloDalton threshold typically associated with such responses. Unlike many collagen stimulators that primarily target Type I collagen — which can lead to thicker, more fibrotic tissue — Linerase promotes the regeneration of Type III collagen, closely associated with youthful, resilient skin. This targeted approach results in more natural, supple outcomes, reinforcing Linerase’s position as a safer and more advanced solution in aesthetic medicine.

“At Linerase, we believe that true skin rejuvenation lies not in covering up imperfections but in restoring the skin’s natural structure and vitality. With Linerase, we are empowering the skin to heal, regenerate, and reveal its healthiest state,” said Prof. Andrea Corbo during his sharing session.

Echoing this sentiment, Dr. Katerina shared, “Linerase fills an important gap in modern aesthetic medicine — offering patients a treatment that not only addresses visible signs of aging but does so in a way that is safe, natural, and scientifically backed. It’s a new chapter for skin health in Malaysia.”

A New Standard in Skin Health

Backed by over 30 years of research from its Italian developer CSD, and certified with ISO 9001 and ISO 13485 standards, Linerase stands at the forefront of regenerative aesthetics. Its scientifically proven efficacy, biocompatibility, and long-lasting natural results set a new benchmark in non-invasive skin rejuvenation.

For more information about Linerase, visit www.linerase.com.

About LINERASE

Linerase is a collagen biostimulator treatment developed by CSD, an Italian company founded in 1997 with a strong heritage in science, research, and aesthetic medicine. Certified with ISO 9001 and ISO 13485, CSD has dedicated the last three decades to advancing dermal biorevitalization technologies, specializing in innovative formulations using native Type I Collagen.

At the heart of Linerase is a commitment to slowing down the aging process by naturally regenerating the skin’s structure, improving firmness, texture, and radiance. Designed to repair and reverse visible signs of skin aging, Linerase offers a cutting-edge approach to aesthetic treatments by stimulating the body’s own collagen production.

Driven by a passion for science and creativity, CSD continues to invest heavily in research and development, expanding its product portfolio in dermal biostimulation and anti-aging solutions. Through global distribution networks, continuous practitioner education, and a strong focus on safety and innovation, Linerase is consolidating its position as a leader in the bioregeneration market worldwide. At Linerase, science meets artistry — offering safe, effective, and natural results for healthier, more youthful skin.

About Venusys Medical

Venusys Medical was incorporated since 2005. The company has since been the pioneer in the distribution of laser , light-based equipment and other multi-technology systems for the aesthetic and surgical markets. We pride ourselves in having all our medical equipment registered and approved by the Ministry of Health Malaysia to meet the stringent demand of the medical industry. Our portfolio focuses on two divisions – Aesthetic equipment and life science research products. We consistently discover new ways to address some of society’s most challenging aesthetic issues.

Our mission is to serve the growing needs of both patients and practitioners. Venusys Medical has strong market positions in the areas of aesthetic dermatology, cosmetics & plastic surgery. We actively market our products to most of the hospitals, private medical centres, and aesthetic physician offices in Malaysia.

Website:                www.linerase.com
Facebook:             www.facebook.com/profile.php?id=61556731348025
Instagram:             www.instagram.com/linerase_sgmy

Cision View original content to download multimedia:https://www.prnewswire.com/apac/news-releases/linerase-officially-launches-in-malaysia-302461511.html

SOURCE Venusys Medical Sdn. Bhd.

​ 

Previous Post

Bank of Sydney subscribes to Infosys Finacle Digital Banking Suite on AWS Cloud

Next Post

WHO Foundation and Laerdal Global Health announce US $12.5 million to launch massive Acute Care scale up aiming to save over 50,000 lives per year

Next Post
WHO Foundation and Laerdal Global Health announce US $12.5 million to launch massive Acute Care scale up aiming to save over 50,000 lives per year

WHO Foundation and Laerdal Global Health announce US $12.5 million to launch massive Acute Care scale up aiming to save over 50,000 lives per year

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

BROWSE BY CATEGORIES

  • Blog
  • Bursa News
  • Corporate Interviews
  • Features Interviews
  • Financial & Investment Articles
  • Financial News
  • Government News
  • Investment News
  • Listing Companies News
  • Oversea Financial & Investment News
  • PR Newswire

BROWSE BY TOPICS

2018 League Balinese Culture Bali United Budget Travel business Champions League Chopper Bike Doctor Terawan industrial Istana Negara Malaysia Market Stories National Exam net zero emissions targets 2025 Renewable energy Visit Bali

Recent News

  • Peter Singer Named to the Inaugural 2025 TIME100 Philanthropy List
  • Peter Singer Named to the Inaugural 2025 TIME100 Philanthropy List
  • Global Times Online: Wuxi and Thailand Deepen Cultural and Tourism Ties, Highlighting the Scenic Appeal of Taihu Lake

Category

  • Blog
  • Bursa News
  • Corporate Interviews
  • Features Interviews
  • Financial & Investment Articles
  • Financial News
  • Government News
  • Investment News
  • Listing Companies News
  • Oversea Financial & Investment News
  • PR Newswire
  • About
  • Advertise
  • Careers
  • Contact

Copyright © 2024 Money Compass Media (M) Sdn Bhd. All Rights Reserved

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Home
  • Features Interviews
  • Government News
  • Financial News
  • Investment News
  • Listing Companies News
  • Corporate Interviews
  • Bursa News
  • Financial & Investment Articles
  • Oversea Financial & Investment News

Copyright © 2024 Money Compass Media (M) Sdn Bhd. All Rights Reserved